Article: Early Experience of High-dose Intravenous
2021 Volume 25, Issue 9, Page(s) 1066–1068
Abstract: ... with decreased O: How to cite this article: Patel PS, Patel S, Shah V, Aswani V, Narwaria M. Early Experience ...
| Abstract | Background: Immune dysregulation is one of the main reasons for mortality and morbidity in coronavirus disease 2019 (COVID-19). Mycobacterium w (Mw) is recently approved for gram-negative sepsis. Moreover, it is also found effective in COVID-19 patients in previous studies. The traditional route of administration for Mw is intradermal, which has a limitation of administering 0.1 mL per injection and local injection site reaction. Intravenous (IV) administration of Mw has not been explored in COVID-19. We report the retrospective analysis of six critically ill COVID-19 patients who received Mw (IV). Patients and methods: At baseline, all patients in this case series required O Results: After Mw administration, gradual improvement in O Conclusion: Use of 0.6 mL Mw by IV route in this case series was associated with decreased O How to cite this article: Patel PS, Patel S, Shah V, Aswani V, Narwaria M. Early Experience of High-dose Intravenous |
|---|---|
| Language | English |
| Publishing date | 2021-12-28 |
| Publishing country | India |
| Document type | Case Reports |
| ZDB-ID | 2121263-6 |
| ISSN | 1998-359X ; 0972-5229 |
| ISSN (online) | 1998-359X |
| ISSN | 0972-5229 |
| DOI | 10.5005/jp-journals-10071-23963 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.